128 results about "With glomerular filtration rate" patented technology

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

A continuous Glomerular Filtration Rate (GFR) estimation system may include a Foley catheter, a continuous urine creatinine sensor, and a urine output monitor. The continuous GFR estimation system computes creatinine clearance as CrCl=(Ucr×Uvol)/(Pcr×Imim), where Ucr is urine creatinine in mg/dL, Uvol is urine volume in mL, Pcr is plasma (serum) creatinine in mL, and Imin is time in minutes. A Foley catheter may be used to withdraw urine from the bladder. The urine may be delivered to a urine output monitor that provides the Uvol value over a time Imin. Attached to the catheter is the flow-through continuous urine creatinine sensor for providing the Ucr value. The remaining parameter is Pcr. Because serum creatinine levels do not change rapidly over time, a blood sample may be withdrawn prior to the start of the continuous GFR to obtain the PCr value.

A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.

Stable isotope labeling and neutron activation to measure biological functions are provided, as are the use and method of adding a chemical monitor to correct for neutron flux to sample vials prior to the addition of sample is presented, and the use of stable isotopes as a chemical bar code for vials and other items. Methods are provided also for measuring glomerular filtration rate and glomerular sieving function in a subject, and for measuring other physiological functions.

The invention provides an in-vitro detection method of human cystatin C. The method adopts a magnetic particle separation chemiluminescence immunoassay technology which is a product integrating an enzyme labeling technology, a magnetic particle separation technology and a chemiluminescence detection technology and has the advantages of high sensitivity, good specificity, good repetitiveness, and the like. The method can be used for measuring the content of cystatin C in the serum, the plasma and the urine of a person, and the indexes are mainly used for clinically evaluating the renal function and mainly used for monitoring the filtration rate of glomerulus, the renal tubular dysfunction and various secondary nephropathies.

The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided.

The invention provides polyethylene glycol modified L-Asparaginasum shown as formula (1) and a modification method thereof. The method uses the modification reaction property of polyethylene glycol molecules to modify the L-Asparaginasum under the condition of proper pH value of a reaction system. The polyethylene glycol modified L-Asparaginasum is characterized in that two polyethylene glycol molecules are covalently bound in a reaction product; and the substance has lower glomerular filtration rate and lower immunogenicity compared with a single polyethylene glycol molecule modifier so as to provide better antitumor effect.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention concerns new chemical compounds that can be used as marker substances in renal diagnostics, their production and use, and renal diagnostic agents which contain them.

The invention discloses an evaluating system for a glomerular filtration rate. The evaluating system for the glomerular filtration rate comprises a patient management module and a system user management module. The patient management module comprises a patient listing module, a patient adding module and patient searching module. The patient listing module is used for displaying all of the patient basic information, testing results and a glomerular filtration rate calculation result. The patient adding module comprises a patient basic information and testing results inputting module and the testing results and a data processing module. The patient searching module is used for searching patient information. The system user management module comprises a user log-in, a user personal profile and a log-out. The system has the advantages that (1) the operation of a clinician and the comparison of GFR changes of patients in different period are convenient to achieve, (2) GFR variations of the patients with different illnesses are compared, (3) GFR data can be saved, so that the analysis on changes of renal function of patients and clinical follow-up are convenient to achieve, (4) a statistical analysis and a summary report are convenient to write.

The invention provides polyethylene glycol modified human interleukin-2 so as to improve the physical and chemical property and the biological activity of interleukin-2 self, in particular Y-type polyethylene glycol NHS ester modified interleukin-2. Compared with the prior art, the Y-type polyethylene glycol NHS ester modified interleukin-2 is similar to polyethylene glycol NHS used in PEGasys in structure and performance, but has better chemical stability. The invention preferably selects the Y-type polyethylene glycol with gross molecular weight of 40kDa to improve the molecular weight, thereby reducing glomerular filtration rate, and improving medicament half life; and adopted branched polyethylene glycol can increase steric hindrance of protein medicinal molecules, thereby significantly reducing the immunogenicity of protein molecules.

The invention provides a construction method of an in-vitro diabetes mellitus glomerulus model based on a micro-fluidic chip. The micro-fluidic chip is mainly formed by upper-layer and lower-layer PDMS through bonding and sealing, and is composed of a cell inlet tank, a collagen inlet tank, a culture medium inlet tank, a waste liquid tank, a cell culture chamber, a culture medium perfusion chamber, a cell ball capture tank and a cell migration chamber, wherein fluid culture stimulation under the conditions with high-sugar 10-30 mM glucose and 1-5 mM glucose low sugar is added on the chip, perfusion is carried out on a side channel for 48h, so that a glomerulus filtration barrier is formed, perfusion with culture mediums with different sugar concentrations is carried out on a main channel for 96h, and thus the in-vitro diabetes mellitus glomerulus model is established. For the diabetes mellitus glomerulus model based on the micro-fluidic chip, the glomerulus filtration barrier can be established, so that the timed monitoring can be carried out on the glomerular filtration rate, meanwhile, the movement of different constituting cells in the glomeruli can be tracked in real time, andmoreover, the accurate positioning for the initial cell movement can be realized.

The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m², or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.

A method for determining the amount of a known iodine-containing organic compound in an aqueous solution. The method comprises electrochemically reducing the known iodine-containing organic compound in an aqueous medium to release iodide anions, chemically oxidizing the iodide anions to produce molecular iodine, and measuring the amount of molecular iodine. The known iodine-containing organic compound is preferably an aryl iodide, such as Iothalamate. Other preferred iodine-containing organic compounds include various glomerular filtration rate (GFR) marker compounds in plasma or urine samples, as useful in the measurement of GFR for an animal. The electrochemical reduction of the known iodine-containing organic compound is preferably performed in an electrochemical cell including a working electrode separated from a counter electrode by a cation exchange membrane. The working electrode most preferably includes bismuth and the counter electrode most preferably includes platinum.